418 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
Is Britain Headed for a Soft Brexit? 5 Picks http://www.zacks.com/stock/news/359442/is-britain-headed-for-a-soft-brexit-5-picks?cid=CS-ZC-FT-359442 Mar 14, 2019 - Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Bayer Submits Application in EU for Prostate Cancer Drug http://www.zacks.com/stock/news/358754/bayer-submits-application-in-eu-for-prostate-cancer-drug?cid=CS-ZC-FT-358754 Mar 11, 2019 - Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps http://www.zacks.com/stock/news/358687/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps?cid=CS-ZC-FT-358687 Mar 11, 2019 - Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-ZC-FT-357836 Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 http://www.zacks.com/stock/news/357189/mallinckrodt-mnk-rallies-as-earnings-beat-estimates-in-q4?cid=CS-ZC-FT-357189 Feb 27, 2019 - Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/357173/bayer-bayry-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-357173 Feb 27, 2019 - Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4241291-astrazeneca-group-plc-azn-ceo-pascal-soriot-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 14, 2019 - AstraZeneca Group plc (NYSE:AZN) Q4 2018 Earnings Conference Call February 14, 2019 7:00 AM ET Company Participants Pascal Soriot - Chief Executive Officer Dave Fredrickson - Executive Vice President,
BMY vs. AZN: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/354650/bmy-vs-azn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-354650 Feb 14, 2019 - BMY vs. AZN: Which Stock Is the Better Value Option?

Pages: 123456789...42

<<<Page 4>